Neuren Pharmaceuticals (ASX:NEU) said its partner Acadia Pharmaceuticals reported 2024 net sales of $348.4 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.
The figure represents a 97% increase from 2023 and is close to the top end of Acadia's guidance of $340 million to $350 million, the filing said.
Acadia, the company's partner for the development and commercialization of the drug, provided a 2025 guidance of between $380 million and $340 million for the US market.
The company expects royalties of AU$56.2 million for 2024 and between AU$62 million and AU$67 million for 2025.
The company's shares rose 8% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.